Time-series analysis of gene expression identifies of FKBP4 as a novel protective factor in severe acute pancreatitis-associated myocardial injury Authors: Xi-Jing Zhuang, Xiao Han, Chang Xu, Peng Ge, Hai-Long Chen Published: 2026 ABSTRACT Acute pancreatitis (AP), a prevalent inflammatory condition, can result in systemic complications, including myocardial injury. Nevertheless, the dynamic transcriptomic alterations and key molecular mechanisms underlying pancreatic-associated cardiac complications during AP progression are still not fully elucidated. Male Sprague-Dawley (SD) rats (8–10 weeks old) were subjected to retrograde infusion of 5% sodium taurocholate into the pancreatic and biliary ducts to induce severe acute pancreatitis (SAP). Myocardial injury was evaluated through echocardiographic assessment, measurement of serum cardiac enzyme levels, and histopathological examination. Temporal gene expression profiles in cardiac tissues were analyzed using microarray technology. A total of 1824 differentially expressed genes (DEGs) were identified in cardiac tissues at 12, and 24 h post-SAP induction compared to Sham controls. These DEGs were predominantly associated with ischemia, hypoxia, apoptosis, mitochondrial fission, and oxidative stress in cardiac tissues following the induction of SAP. Co-expression network analysis revealed that FKBP4, a member of the immunophilin protein family involved in steroid receptor signaling and protein folding, was centrally positioned within the gene network. FKBP4 expression was significantly downregulated in cardiac tissues at all time points following SAP induction. Cardiomyocyte-specific overexpression of FKBP4 markedly attenuated myocardial injury, reduced inflammatory infiltration and oxidative stress, and decreased mitochondrial fission and cardiomyocyte apoptosis. Mechanistically, FKBP4 overexpression upregulated HSP90 and SERCA2 expression, suppressed the activation of Drp1 and p-P65, and ultimately improved cardiac contractile function. These findings suggest that FKBP4 represents a candidate molecule that warrants further mechanistic and preclinical investigation in the context of pancreatitis-associated myocardial injury. Introduction Acute pancreatitis (AP) is a prevalent gastrointestinal emergency defined by pancreatic inflammation and has the potential to progress into a severe systemic condition accompanied by multi-organ dysfunction [1,2]. Among the extrapancreatic complications of acute pancreatitis, myocardial injury is particularly critical, significantly contributing to the mortality associated with severe acute pancreatitis (SAP) [3,4]. Clinically, this cardiac impairment presents as arrhythmias, heart failure, or subclinical systolic dysfunction; however, the underlying pathophysiological mechanisms are complex and not yet fully elucidated. The prevailing mechanistic framework identifies systemic inflammatory cascades, oxidative stress, calcium dysregulation, and mitochondrial dysfunction as central pathophysiological mechanisms underlying cardiac injury associated with SAP [3,5,6]. Nevertheless, the dynamic molecular adaptations and precise regulatory networks within the myocardium during the progression of SAP remain poorly understood and incompletely defined. Accumulating evidence supports the critical involvement of specific genes in SAP-associated myocardial injury [3]. For example, interleukins and tumor necrosis factor-α (TNF-α) have been extensively validated as key mediators of SAP-induced myocardial injury through their regulation of the early inflammatory cascade. miR-29a-3p downregulates HMGB1, leading to reduced expression of pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, and TNF-α, thereby attenuating myocardial injury [7]. Knockdown of MALAT1 inhibits cardiomyocyte apoptosis and alleviates SAP-associated myocardial injury [8]. Moreover, genes involved in oxidative stress, such as NOX2 and NOX4, can modulate cardiomyocyte fate during different phases of SAP by regulating apoptosis through the MAPK signaling pathway [6]. Collectively, these findings suggest that integrative analysis of cardiac dynamic gene regulatory networks may enable a more precise characterization of the molecular mechanisms underlying SAP-induced myocardial injury and facilitate the identification of pivotal therapeutic targets. The advancement of transcriptomic technologies, particularly time-series microarray analysis, has provided a powerful approach for elucidating the temporal dynamics of disease progression [9]. While previous studies have predominantly focused on static endpoints or isolated pathways, a comprehensive longitudinal analysis of the cardiac transcriptome during SAP holds significant potential to uncover novel, stage-specific mediators and therapeutic targets. This study aimed to systematically delineate the temporal transcriptomic landscape of the heart during SAP-induced myocardial injury and to identify and functionally validate key regulatory genes within this network. Utilizing a rat model of SAP, we performed longitudinal RNA sequencing of cardiac tissues. Through integrated bioinformatics and subsequent in vivo functional studies, we identified FKBP4 as a central hub gene. Our results demonstrate that cardiac-specific FKBP4 overexpression confers significant protection against SAP-induced myocardial injury by attenuating inflammation, oxidative stress, mitochondrial fission, and cardiomyocyte apoptosis, thereby improving cardiac contractility. These findings suggest that FKBP4 is a candidate molecule warranting further mechanistic and preclinical investigation for pancreatitis-associated myocardial injury. Methods Animal model and treatment All animal procedures were approved by the Institutional Animal Care and Use Committee of Dalian Medical University (Approval No. AEE23067) and conducted in accordance with the guidelines of the National Institutes of Health (NIH). Male Sprague-Dawley (SD) rats (8–10 weeks old), purchased from SPF Biotechnology Co., Ltd. (Beijing, China), were subjected to SAP induction via retrograde injection of 5% sodium taurocholate (Sigma-Aldrich, St. Louis, MO, USA), as described in previous studies [10,11]. All animals were anesthetized using 1.5% isoflurane (RWD Life Science Co., Ltd., Shenzhen, China). Subsequently, a midline abdominal incision was performed, the biliopancreatic duct was identified, and 5% sodium taurocholate was retrogradely infused into its distal segment at a rate of 0.2 mL/min [10,11].The animals were monitored at 12, 24, and 72 h following surgery. For overexpression experiments, SD rats were intravenously administered recombinant adeno-associated virus serotype 9 encoding FKBP4 (rAAV9-FKBP4, 1.2 × 1012 vg/mL) or a control vector expressing green fluorescent protein (rAAV9-GFP), both sourced from Hanbio Biotechnology Co., Ltd. (Shanghai, China), at a volume of 250 μL four weeks prior to the scheduled experiments. Following a four-week expression period, the animals underwent either sham surgery or induction of SAP. Echocardiography Cardiac function was assessed using transthoracic echocardiography under continuous anesthesia with 1.5% isoflurane (RWD Life Science Co., Ltd., China). M-mode imaging was conducted at 12 and 24 h post-SAP using a 30-MHz transducer (SiliconWave; KOLO, China), in accordance with established standardized protocols [12]. Left ventricular systolic function was evaluated by measuring ejection fraction (EF) and fractional shortening (FS). EF was calculated as: 100 × [(LVEDV – LVESV)/LVEDV] (%), and FS as: 100 × [(LVDd – LVDs)/LVDd] (%), following previously published methodologies [12]. Microarray and bioinformatics analysis Total RNA was extracted from the left ventricular myocardium (n = 5 per group) using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Following fragmentation, approximately 12.5–15 μg of biotinylated cRNA from each sample was subjected to hybridization on the Affymetrix Mouse Genome 430 2.0 Array (Affymetrix, Inc., Santa Clara, CA, USA). Subsequent washing, staining, and scanning procedures were conducted as previously described [13]. The resulting gene expression data have been deposited in the Gene Expression Omnibus (GEO) under accession number GSE313546. For bioinformatics analysis, differentially expressed genes (DEGs) were identified and subjected to Gene Ontology (GO) enrichment analysis, KEGG pathway analysis, and construction of gene co-expression networks. These analytical approaches were applied to identify key genes and signaling pathways associated with SAP-induced myocardial injury, in accordance with previously published methodologies [14,15]. Histological analysis Heart tissue specimens were fixed in 10% neutral buffered formalin and subsequently paraffin-embedded using standard procedures. Consecutive sections of 5 μm thickness were generated and stained with haematoxylin and eosin (H&E) following established methods [12].Frozen sections of the heart (7 μm) were incubated with 10 μmol/L dihydroethidium (DHE) at 37°C for 30 min to evaluate oxidative stress [12]. Apoptosis was assessed by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay using a Colorimetric TUNEL Apoptosis Assay Kit (Beyotime, Shanghai, China) [16]. Light and fluorescence images were acquired using a SOPTOP CX40 microscope (Ningbo Sunny Instruments Co., Ltd., China) and subsequently subjected to quantitative analysis with ImageJ software (National Institutes of Health, Bethesda, MD, USA). Transmission electron microscopy (TEM) Myocardial tissue was harvested from SAP-and sham-operated mice (n = 3 per group). Following glutaraldehyde (2.5%, 4°C, 24 h) and osmium tetroxide (1%, 2 h) fixation, LV ischemic tissue blocks (∼1 mm3) were processed through dehydration and epoxy resin embedding. Ultrathin sections (50–70 nm) were prepared with a microtome (UC7, Leica, Germany) and stained with 2% uranyl acetate and lead citrate [17]. Images were captured using a JEM-1400 PLUS transmission electron microscope (JEOL, Japan). Mitochondrial morphology was analyzed across five randomly selected fields per sample using ImageJ software (National Institutes of Health, Bethesda, MD, USA). ATP assay Cardiac ATP content was determined using a commercial assay kit (#S0027, Beyotime, Beijing, China) according to the manufacturer's instructions. Fresh tissue samples (20 mg) were washed with phosphate-buffered saline (PBS), homogenized in ATP assay buffer, and centrifuged at 12,000 × g for 5 min at 4°C. The supernatant was then incubated with the detection probe for 30 min at room temperature in the dark. Absorbance was measured at 570 nm using a Tecan Infinite M1000 PRO microplate reader (Tecan Trading AG, Switzerland). ATP levels were normalized to total protein content. Plasma CK-MB, LDH, lipase and amylase activity assay The plasma levels of CK-myocardial band (CK-MB), and lipase activity were detected using ELISA kits (#E-EL-R1327 and #E-BC-K786-M, Elabscience, Wuhan, China) according to the manufacturer's instructions. The plasma lactate dehydrogenase (LDH) level was determined using the microplate method with an LDH assay kit (#A020-2, Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Amylase activity was determined using an α-amylase activity assay kit (#P0405S, Beyotime, Beijing, China). Quantitative real-time PCR analysis Total RNA was extracted from left ventricular myocardium using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and subsequently reverse transcribed into complementary DNA (cDNA) with a commercial RT Enzyme Mix (Accurate Biotechnology Co., Ltd., Hunan, China), following the manufacturer's instructions. Quantitative Real-Time PCR (qRT-PCR) was performed on an PCR Thermal Cycler System (LongGene Co., Ltd., Hangzhou, China) to determine the mRNA expressions described previously [12,18]. Transcript levels were normalized to the endogenous reference gene GAPDH. The sequences of gene primers are provided in Table 1.Table 1RNA primer sequence used in Real-time quantitative PCR.Table 1GeneForward primerReverse primerFkbp4ACCGTGTACTTCAAGGAAGGCCTGTCTTCACCTGAGCCTGGIL-1βTCCTCTGTGACTCGTGGGATGTTTGGGATCCACACTCTCCAIL-6CACTTCACAAGTCGGAGGCTAGCACACTAGGTTTGCCGAGTNF-αTAGCCCACGTCGTAGCAAACAATTCTGAGCCCGGAGTTGGGAPDHCTCTCTGCTCCTCCCTGTTCCGATACGGCCAAATCCGTTC Table 1RNA primer sequence used in Real-time quantitative PCR.Table 1GeneForward primerReverse primerFkbp4ACCGTGTACTTCAAGGAAGGCCTGTCTTCACCTGAGCCTGGIL-1βTCCTCTGTGACTCGTGGGATGTTTGGGATCCACACTCTCCAIL-6CACTTCACAAGTCGGAGGCTAGCACACTAGGTTTGCCGAGTNF-αTAGCCCACGTCGTAGCAAACAATTCTGAGCCCGGAGTTGGGAPDHCTCTCTGCTCCTCCCTGTTCCGATACGGCCAAATCCGTTC RNA primer sequence used in Real-time quantitative PCR. Western blot analysis Snap-frozen heart samples were homogenized in RIPA lysis buffer supplemented with protease inhibitors (Solarbio Science Technology Co., China). Protein concentrations were determined, and equal amounts (50 μg per lane) were resolved by 10% SDS-PAGE. Following electrophoresis, proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The membranes were then incubated overnight at 4°C with primary antibodies (Table 2). After washing, membranes were probed with appropriate horseradish peroxidase-conjugated secondary antibodies. Protein bands were visualized using an ECL Plus chemiluminescence system (Shenhua Science Technology Co., Ltd., Hangzhou, China). The signal intensities were quantified with ImageJ software (National Institutes of Health, Bethesda, MD, USA), and protein expression levels were normalized to GAPDH as an internal control.Table 2Primary Antibodies used in immunoblot analysis.Table 2AntibodyCampanyProduct numberDilution ratioFkbp4proteintech106551-AP1:1000Baxproteintech50599-2-Ig1:1000Bcl-2proteintech26593-1-AP1:1000Caspase-3proteintech19677-1-AP1:1000HSP90Biossbsm-51215 M1:1000SERCA2ABclonalA116921:1000p-Drp1ser616Cell Signaling Technolog3455S1:1000Drp1Cell Signaling Technolog5391S1:2000p-P65ArigobioARG656771:1000P65ArigobioARG515181:2000GAPDHCell Signaling Technolog5174s1:5000 Table 2Primary Antibodies used in immunoblot analysis.Table 2AntibodyCampanyProduct numberDilution ratioFkbp4proteintech106551-AP1:1000Baxproteintech50599-2-Ig1:1000Bcl-2proteintech26593-1-AP1:1000Caspase-3proteintech19677-1-AP1:1000HSP90Biossbsm-51215 M1:1000SERCA2ABclonalA116921:1000p-Drp1ser616Cell Signaling Technolog3455S1:1000Drp1Cell Signaling Technolog5391S1:2000p-P65ArigobioARG656771:1000P65ArigobioARG515181:2000GAPDHCell Signaling Technolog5174s1:5000 Primary Antibodies used in immunoblot analysis. Culture of rat H9c2 cardiomyocytes and assessment of mitochondrial respiration H9C2 cardiomyocytes were maintained in DMEM (Lonza, Belgium) supplemented with 10% fetal calf serum (Gbico, Australia), 25 mM HEPES, and 100 μg/mL each of ampicillin and carbenicillin, incubated at 37°C in a humidified 5% CO2 atmosphere. H9C2 cardiomyocytes were infected with Ad-GFP alone, or Ad-APIP for 24 h, followed by treatment with 1 ng/μL LPS (L2637, Sigma, Germany) or PBS for an additional 24 h. Measurements of cellular oxygen consumption were performed using the Oxygraph-2k system (Oroboros Instruments, Austria). Mitochondrial respiration was measured under basal conditions (routine respiration) and sequentially following the addition of 1.5 μM oligomycin (to assess proton leak respiration), 1 μM carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) (to determine maximal uncoupled respiration), and then 2.5 μM antimycin A combined with 1.25 μM rotenone (to measure residual respiration), as previously described [19,20]. Statistical analysis Data are expressed as mean ± standard error of the mean (SEM). Differences between two experimental groups were assessed using an unpaired, two-tailed Student's t-test. For comparisons among more than two groups, one-way analysis of variance (ANOVA) was used, followed by the Newman–Keuls post hoc test for multiple comparisons. All statistical analyses were performed with GraphPad Prism software (Version 5, GraphPad Software, USA). A P-value < 0.05 was considered statistically significant. Results Induction of SAP exacerbates cardiac injury in rats To investigate gene expression changes associated with cardiac injury during severe acute pancreatitis (SAP), male SD rats were administered 5% sodium taurocholate via retrograde infusion into the biliopancreatic duct over a time course of 12 to 72 h. Consistent with SAP progression, mortality increased in a time-dependent manner compared to sham-operated controls (Fig. 1a). Elevated plasma amylase and lipase activities were observed in SAP rats, accompanied by impaired cardiac function as indicated by reduced ejection fraction (EF%) and fractional shortening (FS%) (Fig. 1b–d). Histological evaluation further revealed time-dependent increases in cardiac reactive oxygen species (ROS), inflammatory cell infiltration, and TUNEL-positive nuclei (Fig. 1e and f).Fig. 1Induction of severe acute pancreatitis (SAP) exacerbates cardiac injury in rats.(a) Kaplan-Meier survival curves of sham-operated and SAP-induced rats over 72 h (n = 12). (b-c) Quantification of plasma amylase and lipase activities (n = 8). (d) Echocardiographic assessment of cardiac function [ejection fraction (EF%) and fractional shortening (FS%)] (right panel) at indicated time points post-SAP induction (n = 6). (e) Representative images of H&E and DHE staining of heart tissues from sham and SAP groups (left, n = 6), Scale bars, 100 μm. Quantitative analysis of cardiac ROS level (right, n = 6). (f) Representative images of TUNEL staining of the heart sections (left), and quantification of TUNEL-positive nuclei (right, n = 6). Scale bar: 100 μm. Data are expressed as mean ± standard error of the mean (SEM), where n represents the number of animals. Statistical significance was defined as P < 0.05. Induction of severe acute pancreatitis (SAP) exacerbates cardiac injury in rats. (a) Kaplan-Meier survival curves of sham-operated and SAP-induced rats over 72 h (n = 12). (b-c) Quantification of plasma amylase and lipase activities (n = 8). (d) Echocardiographic assessment of cardiac function [ejection fraction (EF%) and fractional shortening (FS%)] (right panel) at indicated time points post-SAP induction (n = 6). (e) Representative images of H&E and DHE staining of heart tissues from sham and SAP groups (left, n = 6), Scale bars, 100 μm. Quantitative analysis of cardiac ROS level (right, n = 6). (f) Representative images of TUNEL staining of the heart sections (left), and quantification of TUNEL-positive nuclei (right, n = 6). Scale bar: 100 μm. Data are expressed as mean ± standard error of the mean (SEM), where n represents the number of animals. Statistical significance was defined as P < 0.05. Temporal gene expression profiling in cardiac tissues following induction of SAP To characterize the temporal gene expression dynamics during SAP-induced cardiac injury, we conducted a time-series microarray analysis on cardiac tissues collected at 12 and 24 h after the induction of SAP (n = 5 per time point). Compared with sham-operated controls, 1824 differentially expressed genes (DEGs; P < 0.05, FC ≥ 1.5) were identified across the time course (Fig. 2a). Temporal profiling showed 604 up- and 624 down-regulated genes at 12h, 363 up- and 601 down-regulated at 24h, with a total of 507 DEGs commonly dysregulated at both time points. (Fig. 2b–c). Gene Ontology (GO) enrichment analysis of these differentially expressed genes (DEGs) revealed significant enrichment in molecular functions associated with ischemia, hypoxia, apoptosis, oxidative stress, and mitochondrial fission (Fig. 2d). KEGG pathway analysis further identified significantly altered pathways involved in SAP-related cardiac injury, including the PI3K-AKT signaling pathway, apoptosis, MAPK signaling pathway, mitochondrial biogenesis, and HIF-1 signaling pathway (Fig. 2e).Fig. 2Temporal association between SAP progression and cardiac gene expression dynamics(a) Heatmap showing the hierarchical clustering of 1824 differentially expressed genes (DEGs) in cardiac tissues from Sham, SAP 12h, and SAP 24h groups (n = 5). (b) Scatter plots showing the distribution of differentially expressed genes at 12 h and 24 h post-SAP, with the numbers of up-regulated, down-regulated, and unchanged genes indicated for each time point. (c) Venn diagrams depicting the overlapping between the two time points. (d) Gene Ontology (GO) enrichment analysis of biological processes for the identified DEGs. Top 10 significantly enriched terms are shown. (e) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for the DEGs. Top 10 significantly enriched pathways are displayed. Temporal association between SAP progression and cardiac gene expression dynamics (a) Heatmap showing the hierarchical clustering of 1824 differentially expressed genes (DEGs) in cardiac tissues from Sham, SAP 12h, and SAP 24h groups (n = 5). (b) Scatter plots showing the distribution of differentially expressed genes at 12 h and 24 h post-SAP, with the numbers of up-regulated, down-regulated, and unchanged genes indicated for each time point. (c) Venn diagrams depicting the overlapping between the two time points. (d) Gene Ontology (GO) enrichment analysis of biological processes for the identified DEGs. Top 10 significantly enriched terms are shown. (e) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for the DEGs. Top 10 significantly enriched pathways are displayed. Co-expression network analysis identifies FKBP4 as a central hub gene To identify key regulators of cardiac injury in SAP, a weighted gene co-expression network was constructed from differentially expressed genes (DEGs) using the k-core algorithm and betweenness centrality analysis. Topological network analysis identified FKBP4 as a central hub gene, directly interconnected with 30 neighboring nodes (Fig. 3a). FKBP4 exhibited significantly higher degree and betweenness centrality values than other genes in the network, highlighting its pivotal regulatory role. Microarray analysis, followed by qRT-PCR validation, confirmed that FKBP4 mRNA expression was progressively downregulated in cardiac tissues at 12 and 24 h after SAP induction (Fig. 3b). This transcriptional downregulation was further validated at the protein level by immunoblotting, demonstrating a consistent time-dependent decrease in FKBP4 expression during SAP progression (Fig. 3c). H9C2 FKBP4 expression expression (Fig. 3d) Collectively, these findings indicate that FKBP4 may serve as a potential master regulator in the pathogenesis of SAP-induced cardiac injury.Fig. 3Co-expression network analysis identify FKBP4 as a central hub gene in SAP-induced cardiac injury.(a) Subnetwork of the gene co-expression network analysis highlighting FKBP4 as a central hub gene directly connected to 30 neighboring genes. Node size corresponds to degree centrality. (b) Validation of FKBP4 mRNA expression by microarray and quantitative real-time PCR (qRT-PCR) in cardiac tissues at 12 h and 24 h after SAP induction (n = 5). (c) Representative immunoblot images (upper) and quantitative analysis (lower) of FKBP4 protein expression in cardiac tissues from the sham, SAP 12 h, and SAP 24 h groups (n = 4). (d) Representative immunoblot images (upper) and quantitative analysis (lower) of FKBP4 protein expression in H9C2 cells (n = 4). GAPDH was used as a loading control. Data are expressed as mean ± SEM, where n represents the number of animals. Statistical significance was defined as P < 0.05. Co-expression network analysis identify FKBP4 as a central hub gene in SAP-induced cardiac injury. (a) Subnetwork of the gene co-expression network analysis highlighting FKBP4 as a central hub gene directly connected to 30 neighboring genes. Node size corresponds to degree centrality. (b) Validation of FKBP4 mRNA expression by microarray and quantitative real-time PCR (qRT-PCR) in cardiac tissues at 12 h and 24 h after SAP induction (n = 5). (c) Representative immunoblot images (upper) and quantitative analysis (lower) of FKBP4 protein expression in cardiac tissues from the sham, SAP 12 h, and SAP 24 h groups (n = 4). (d) Representative immunoblot images (upper) and quantitative analysis (lower) of FKBP4 protein expression in H9C2 cells (n = 4). GAPDH was used as a loading control. Data are expressed as mean ± SEM, where n represents the number of animals. Statistical significance was defined as P < 0.05. Cardiomyocyte-specific overexpression of FKBP4 attenuates SAP-induced myocardial injury To investigate the functional role of FKBP4, we employed AAV9-mediated gene delivery to achieve cardiomyocyte-specific overexpression of FKBP4 (Fig. 4b). This intervention reduced mortality in rats with SAP at 24 h compared to those treated with the control rAAV9-GFP vector; however, no statistically significant difference was observed between the two groups (Fig. 4a). FKBP4 overexpression significantly improved cardiac function, as evidenced by the recovery of left ventricular ejection fraction (LVEF) and fractional shortening (FS) following SAP induction (Fig. 4c). It also reduced plasma CK-MB levels and ameliorated myocardial fiber disarray, partial myocardial fiber rupture and lysis, and dilated intercellular spaces (Fig. 4d and e). Moreover, elevated LDH levels, myocardial oxidative stress, and inflammatory cell recruitment (demonstrated by DHE and H&E staining) were significantly attenuated in rAAV9-FKBP4-treated rats compared to those in the rAAV9-control group (Fig. 4f–h). Additionally, SAP-induced increases in IL-1β, IL-6, and TNF-α levels were markedly reduced in rAAV9-FKBP4-treated rats (Fig. 4i).Fig. 4Cardiomyocyte-specific overexpression of FKBP4 attenuates SAP-induced myocardial injury in vivo.(a) Survival rates at 24 h post-SAP induction in rats pre-treated with rAAV9-control (GFP) or rAAV9-FKBP4 (n = 10). (b) Representative immunoblot images (upper) and quantitative analysis (lower) of FKBP4 protein expression in cardiac tissues (n = 4). (c) Representative M-mode echocardiograms depicting left ventricular (left). Quantitative analyses of cardiac function parameters-including EF% and FS% (right, n = 8). (d) Representative H&E staining images of heart sections (n = 5). Scale bar, 100 μm. (e) Plasma levels of creatine kinase-MB (CK-MB) (n = 8). (f) Representative images and quantitative analysis of myocardial ROS assessed by DHE staining (left). Scale bar, 50 μm. Quantitative analysis of cardiac ROS level (right, n = 5). (g) Representative images and quantitative analysis of myocardial inflammatory cell recruitment assessed by H&E staining (left, n = 5). Scale bar, 100 μm. (h) Quantification of plasma lactate dehydrogenase (LDH) activity (n = 6). (i) Cardiac tissue mRNA levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) measured by qPCR (n = 5). Data are expressed as mean ± SEM, where n represents the number of animals. Statistical significance was defined as P < 0.05. Cardiomyocyte-specific overexpression of FKBP4 attenuates SAP-induced myocardial injury in vivo. (a) Survival rates at 24 h post-SAP induction in rats pre-treated with rAAV9-control (GFP) or rAAV9-FKBP4 (n = 10). (b) Representative immunoblot images (upper) and quantitative analysis (lower) of FKBP4 protein expression in cardiac tissues (n = 4). (c) Representative M-mode echocardiograms depicting left ventricular (left). Quantitative analyses of cardiac function parameters-including EF% and FS% (right, n = 8). (d) Representative H&E staining images of heart sections (n = 5). Scale bar, 100 μm. (e) Plasma levels of creatine kinase-MB (CK-MB) (n = 8). (f) Representative images and quantitative analysis of myocardial ROS assessed by DHE staining (left). Scale bar, 50 μm. Quantitative analysis of cardiac ROS level (right, n = 5). (g) Representative images and quantitative analysis of myocardial inflammatory cell recruitment assessed by H&E staining (left, n = 5). Scale bar, 100 μm. (h) Quantification of plasma lactate dehydrogenase (LDH) activity (n = 6). (i) Cardiac tissue mRNA levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) measured by qPCR (n = 5). Data are expressed as mean ± SEM, where n represents the number of animals. Statistical significance was defined as P < 0.05. FKBP4 protects against myocardial injury by alleviating mitochondrial fission and apoptosis To investigate the mechanism underlying the cardioprotective effect of FKBP4, we examined its impact on mitochondrial fission and apoptosis. As anticipated, rAAV9-mediated cardiomyocyte-specific overexpression of FKBP4 effectively attenuated SAP-induced mitochondrial fragmentation and restored cardiac ATP levels, compared with rAAV9-GFP-treated controls (Fig. 5a and b). We next assessed apoptosis using TUNEL staining. At 24 h post-SAP, the percentage of TUNEL-positive cardiomyocytes was significantly lower in rats receiving rAAV9-FKBP4 than in those administered the rAAV9-GFP control vector. Moreover, the SAP-induced increase in pro-apoptotic protein expression (reflected by the elevated Bax/Bcl-2 ratio and cleaved caspase-3 levels) was markedly suppressed by FKBP4 overexpression (Fig. 5c and d). Previous studies have demonstrated that FKBP4, as a key regulator of HSP90 function, not only contributes to the maintenance of mitochondrial function but also preserves intracellular calcium homeostasis by stabilizing SERCA2. Furthermore, it may modulate inflammatory responses through regulation of the NF-κB signaling pathway [[21], [22], [23]]. Western blot analysis revealed that SAP induction significantly decreased the expression levels of HSP90 and SERCA2, while markedly increasing those of Drp1, p-Drp1 (Ser616), and p-NF-κB (P65). Notably, FKBP4 overexpression effectively reversed these alterations (Fig. 5e). Thus, our findings indicate that FKBP4 may act as a key mediator in SAP-induced myocardial injury.Fig. 5FKBP4 protects against myocardial injury by alleviating mitochondrial fission and apoptosis in vivo.(a) Representative transmission electron microscopy (TEM) images of cardiac mitochondria from the indicated groups. Scale bar, 2 μm. Quantitative analysis of mitochondrial fission (right, n = 3). (b) Quantitative analysis of cardiac tissue ATP content (n = 9). (c) Representative TUNEL staining images of heart sections. Scale bar, 100 μm. Quantitative analysis of TUNEL-positive cardiomyocytes (right, n = 5). (d) Representative western blots (left) with quantitative data (right) for Bax, Bcl-2, and cleaved caspase-3 protein levels (n = 4). (e) Representative western blots (left) and quantitative analysis (right) of HSP90, SERCA2, Drp1, p-Drp1 (Ser616), and p-P65 protein expression in heart tissues from the indicated groups (n = 4). GAPDH served as a loading control. Data are expressed as mean ± SEM, where n represents the number of animals. Statistical significance was defined as P < 0.05. FKBP4 protects against myocardial injury by alleviating mitochondrial fission and apoptosis in vivo. (a) Representative transmission electron microscopy (TEM) images of cardiac mitochondria from the indicated groups. Scale bar, 2 μm. Quantitative analysis of mitochondrial fission (right, n = 3). (b) Quantitative analysis of cardiac tissue ATP content (n = 9). (c) Representative TUNEL staining images of heart sections. Scale bar, 100 μm. Quantitative analysis of TUNEL-positive cardiomyocytes (right, n = 5). (d) Representative western blots (left) with quantitative data (right) for Bax, Bcl-2, and cleaved caspase-3 protein levels (n = 4). (e) Representative western blots (left) and quantitative analysis (right) of HSP90, SERCA2, Drp1, p-Drp1 (Ser616), and p-P65 protein expression in heart tissues from the indicated groups (n = 4). GAPDH served as a loading control. Data are expressed as mean ± SEM, where n represents the number of animals. Statistical significance was defined as P < 0.05. FKBP4 overexpression directly attenuates LPS-induced reductions in mitochondrial respiration and apoptosis in cardiomyocytes in vitro To establish a direct causal relationship and elucidate the underlying cellular mechanisms, we utilized an in vitro model based on the rat cardiomyoblast cell line H9c2. We first investigated whether the cardioprotective effects of FKBP4 involve the preservation of mitochondrial bioenergetics. Using high-resolution respirometry, we assessed key parameters of mitochondrial function in intact H9c2 cells. LPS exposure (1 μg/mL for 24 h) significantly impaired mitochondrial respiration, as evidenced by reductions in routine respiration, ATP production, and maximal respiratory capacity (Fig. 6a and b). Strikingly, adenovirus-mediated overexpression of FKBP4 (Ad-FKBP4) prior to LPS challenge effectively restored these parameters to near-baseline levels (Fig. 6b). The ATP kit assay also confirmed that overexpression of FKBP4 effectively restored LPS-induced reductions in ATP levels in cardiomyocytes (Fig. 6c). Consistent with the respiratory data, LPS treatment induced significant cardiomyocyte apoptosis, as evidenced by an elevated Bax/Bcl-2 ratio and increased levels of cleaved caspase-3; these pro-apoptotic effects were markedly attenuated by FKBP4 overexpression (Fig. 6d and e). Furthermore, LPS exposure decreased HSP90 and SERCA2 expression but increased Drp1, p-Drp1 (Ser616), and p-NF-κB-P65 levels; all of these changes were effectively reversed by FKBP4 overexpression in cardiomyocytes (Fig. 6f).Fig. 6FKBP4 overexpression directly attenuates LPS-induced mitochondrial dysfunction and apoptosis in cardiomyocytes in vitro.(a) Oxygen consumption rate (OCR) profiles of H9c2 cells under the following conditions: PBS + Ad-GFP, LPS + Ad-GFP, PBS + Ad-FKBP4, and LPS + Ad-FKBP4. (b) Key mitochondrial respiration parameters derived from the OCR trace: basal respiration, ATP production, and maximal respiration (n = 6 independent experiments). (c) Intracellular ATP levels measured in H9c2 cells of the indicated groups (n = 8). (d-e) Representative western blots for Fkpb4, Bax, Bcl-2, and cleaved caspase-3 in H9c2 cells. Quantitative analysis of the FKBP4, Bax/Bcl-2 ratio and cleaved caspase-3 level normalized to GAPDH (n = 4). (f) Representative western blots and quantitative analysis of HSP90, SERCA2, Drp1, p-Drp1 (Ser616), and p-P65 protein expression in H9c2 cells from the indicated groups (n = 4). GAPDH served as a loading control. Data are expressed as mean ± SEM, where n represents the number of animals. Statistical significance was defined as P < 0.05. FKBP4 overexpression directly attenuates LPS-induced mitochondrial dysfunction and apoptosis in cardiomyocytes in vitro. (a) Oxygen consumption rate (OCR) profiles of H9c2 cells under the following conditions: PBS + Ad-GFP, LPS + Ad-GFP, PBS + Ad-FKBP4, and LPS + Ad-FKBP4. (b) Key mitochondrial respiration parameters derived from the OCR trace: basal respiration, ATP production, and maximal respiration (n = 6 independent experiments). (c) Intracellular ATP levels measured in H9c2 cells of the indicated groups (n = 8). (d-e) Representative western blots for Fkpb4, Bax, Bcl-2, and cleaved caspase-3 in H9c2 cells. Quantitative analysis of the FKBP4, Bax/Bcl-2 ratio and cleaved caspase-3 level normalized to GAPDH (n = 4). (f) Representative western blots and quantitative analysis of HSP90, SERCA2, Drp1, p-Drp1 (Ser616), and p-P65 protein expression in H9c2 cells from the indicated groups (n = 4). GAPDH served as a loading control. Data are expressed as mean ± SEM, where n represents the number of animals. Statistical significance was defined as P < 0.05. Discussion The pathophysiological mechanisms of SAP-associated acute cardiac injury closely resemble those of sepsis-induced cardiomyopathy, with cardiac structural damage and dysfunction linked to elevated trypsin, inflammatory cytokines, reactive oxygen species, and endotoxins [24]. Notably, SAP-induced myocardial injury shares features with sepsis-related myocardial dysfunction rather than classic acute myocarditis, being driven by sterile systemic inflammatory response syndrome-mediated pyroptosis without lymphocytic infiltration, whereas the latter involves viral or autoimmune lymphocytic myocarditis [24] Thus, we consider SAP-associated cardiac impairment a systemic inflammatory response syndrome/sepsis-related myocardial dysfunction-like phenotype. Previous clinical studies have shown that SAP-associated myocardial injury is pathophysiologically distinct from ischemic injury and viral myocarditis, being primarily driven by systemic inflammatory response syndrome and microcirculatory dysfunction, or direct pathogen invasion in infectious cases, rather than coronary atherosclerosis or direct cardiomyocyte viral infection [4]. Clinically, it features a 48% fulminant rate, mean left ventricular ejection fraction approximately 33%, and 22% in-hospital mortality, with injury severity unrelated to pancreatic enzyme levels. Cardiac magnetic resonance remains the diagnostic gold standard, typically showing myocardial edema on T2-weighted imaging and subepicardial or mid-wall late gadolinium enhancement, which contrasts sharply with the subendocardial pattern of ischemic injury, while cardiac dysfunction is often reversible in survivors, underscoring the need for early cardiac magnetic resonance-based recognition over routine coronary angiography in this population [4]. However, imaging-based phenotyping alone cannot capture the underlying molecular heterogeneity. Emerging multi-omics technologies, including genomics, transcriptomics, and proteomics, hold promise for advancing the therapeutic landscape of SAP-associated acute cardiac injury by enabling the identification of novel molecular targets and the development of personalized treatment strategies [25]. This study presents a comprehensive and time-resolved analysis of the molecular pathogenesis underlying myocardial injury induced by SAP. Through the integration of temporal transcriptomic profiling with in vivo and in vitro functional validation, we identify FKBP4 as a central regulatory hub, the downregulation of which contributes critically to SAP-induced myocardial injury pathogenesis. Notably, FKBP4 was persistently dysregulated at both 12 h and 24 h post-SAP, underscoring its sustained and time-dependent contribution to the progression of SAP-associated cardiac injury. Cardiomyocyte-specific overexpression of FKBP4 confers substantial protection by attenuating cardiac dysfunction, structural damage, oxidative stress, and the release of inflammatory cytokines. Mechanistically, FKBP4 exerts its cardioprotective effects through the preservation of mitochondrial respiratory function, inhibition of excessive mitochondrial fission, suppression of apoptosis, and modulation of the HSP90/SERCA2, Drp1 and NF-κB signaling pathways. These findings establish FKBP4 not merely as a biomarker, but as a pivotal regulatory molecule and a promising therapeutic target for cardiac complications associated with SAP. FK506 binding protein 4 (FKBP4), also known as FKBP52, is a member of the immunophilin family and functions as a critical co-chaperone in the mature steroid receptor heterocomplex, primarily regulating the trafficking and activity of glucocorticoid, androgen, and progesterone receptors [26,27]. Beyond its canonical role in steroid hormone signaling, accumulating evidence has established FKBP4 as a multifunctional protein involved in various pathological processes, with biological functions extending to protein folding, regulation of apoptosis, modulation of inflammation, and maintenance of mitochondrial homeostasis [28]. Additionally, studies have shown that FKBP4 contributes to the pathophysiology of cardiovascular diseases. For example, FKBP4 enhances TRPC3-mediated membrane currents and calcium influx, leading to the activation of calcineurin and nuclear factor of activated T-cells (NFAT) within the transient receptor potential pathway, which subsequently promotes pathological hypertrophy of cardiomyocytes in chronic heart disease [29]. Our discovery that FKBP4 expression is suppressed during SAP and that its restoration is profoundly protective unveils a novel, hormone receptor-independent cardioprotective role. The in vivo benefits-improved systolic function, reduced Inflammatory factors release, mitochondrial fission and cardiomyocyte apoptosis and diminished histopathological injury-were mirrored and mechanistically dissected in our in vivo model (Fig. 4, Fig. 5). The finding that FKBP4 overexpression preserved mitochondrial respiration and ATP synthesis in LPS-challenged cardiomyocytes is pivotal (Fig. 6). Mitochondria are both the powerhouses of the cardiomyocyte and central integrators of stress signals; their dysfunction is a final common pathway leading to bioenergetic crisis and cell death [30]. By maintaining oxidative phosphorylation, FKBP4 directly sustains the energy supply essential for cardiac contractility and cellular homeostasis. The molecular mechanisms downstream of FKBP4 appear to be multifaceted, collectively contributing to the preservation of cellular integrity in response to SAP-induced injury. First, we demonstrate that FKBP4 inhibits pathological mitochondrial fission. The reversal of Drp1 upregulation and its activating phosphorylation at Ser616 provides a mechanistic basis for the observed reduction in mitochondrial fragmentation and the concomitant improvement in bioenergetic function. Uncontrolled fission promotes excessive mitochondrial ROS production and the release of pro-apoptotic factors, exacerbating cellular damage [31]. Second, FKBP4 potently suppresses the mitochondrial apoptosis pathway by rebalancing the Bax/Bcl-2 ratio and inhibiting caspase-3 activation. This anti-apoptotic effect is likely a direct consequence of enhanced mitochondrial integrity. Third, our data indicate that FKBP4 may exert part of its protective effects through modulation of the HSP90 chaperone system. The restoration of HSP90 levels and its critical client protein, the sarcoplasmic/endoplasmic reticulum calcium ATPase SERCA2, suggests a role for FKBP4 in maintaining proper protein folding and calcium homeostasis—both of which are essential for cardiomyocyte survival and contractile function. Finally, the attenuation of NF-κB-P65 phosphorylation indicates that FKBP4 also mitigates sustained inflammatory signaling within cardiomyocytes, thereby interrupting a vicious cycle in which local inflammation further amplifies myocardial injury. No study to date has directly investigated the role of FKBP4 in SAP-associated complications The role of FKBP4 in SAP-associated complications beyond the heart has not been directly investigated. Moreover, although we hypothesize that FKBP4 may serve as a general mediator of SAP-related organ injuries, this possibility requires experimental verification. Future studies are warranted to examine FKBP4 expression levels across multiple organs, including the pancreas, lung, kidney, and heart, in SAP models, and to employ tissue-specific knockdown or overexpression strategies to further validate its broader pathological role. Conclusion In summary, our study delineated the dynamic transcriptomic alterations in cardiac tissue following SAP, identifying 1824 differentially expressed genes (DEGs). Among these, FKBP4 emerged as a central regulatory node within the gene co-expression network and demonstrated significant cardioprotective effects. Collectively, these observations position FKBP4 as a candidate molecule warranting further mechanistic and preclinical investigation in the context of pancreatitis-associated myocardial injury. Future studies should aim to elucidate the upstream mechanisms underlying FKBP4 downregulation during SAP and to validate its therapeutic potential through genetic approaches using tissue-specific transgenic and knockout animal models. Author contributions Xijing Zhuang: Conceptualization, Validation, Investigation, Writing – Original Draft, Data Curation, Project Administration. Xiao Han: Data Curation, Formal Analysis. Chang Xu and Peng Ge: Methodology, Data Curation, Formal Analysis. Hailong Chen: Project Administration, Funding Acquisition, Writing – Review & Editing. Ethics declaration This study was conducted in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. This study was approved by the Animal Experimental Ethical Inspection Form of Dalian Medical University. Ethical approval All animal experiments were conducted in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee of Dalian Medical University (Approval No. AEE23067). Data availability The datasets generated and analyzed during the current study are not publicly available due to ongoing research extensions but are available from the corresponding author upon reasonable request. Declaration of generative AI and AI-assisted technologies in the writing process The authors did not use generative AI or AI-assisted technologies in the development of this manuscript. Funding This study was supported by the 10.13039/501100001809National Natural Science Foundation of China (NO. 82574186 and 82274311) Declaration of competing interest All the authors have reviewed the final version of the manuscript and approved it for publication. To the best of our knowledge and belief, this manuscript has not been published in whole or in part nor is it being considered for publication elsewhere. We certify that authors have no conflicts of relevant interests in the manuscript.